NCT01735006 2020-02-24
Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent(Type 16/18 )Vaccine
Xiamen University
Phase 3 Completed
Xiamen University
GlaxoSmithKline
GlaxoSmithKline
Merck Sharp & Dohme LLC
GlaxoSmithKline
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
University of British Columbia
Merck Sharp & Dohme LLC